Bempedoic Acid + Ezetimibe + Placebos
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemias
Conditions
Hyperlipidemias
Trial Timeline
Oct 23, 2017 → Jul 18, 2018
NCT ID
NCT03337308About Bempedoic Acid + Ezetimibe + Placebos
Bempedoic Acid + Ezetimibe + Placebos is a phase 3 stage product being developed by Esperion Therapeutics for Hyperlipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT03337308. Target conditions include Hyperlipidemias.
What happened to similar drugs?
2 of 4 similar drugs in Hyperlipidemias were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03337308 | Phase 3 | Completed |
Competing Products
5 competing products in Hyperlipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Evolocumab + Statins (Cardiovascular Agents) | Amgen | Approved | 39 |
| atorvastatin + atorvastatin + atorvastatin | Pfizer | Approved | 43 |
| SAL003 140 mg + Placebo | Shenzhen Salubris Pharmaceuticals | Phase 3 | 40 |
| SAL003 140 mg + Placebo | Shenzhen Salubris Pharmaceuticals | Phase 3 | 40 |
| SLN360 + Placebo | Medpace | Phase 1 | 26 |